UK paediatric oncology Pneumocystis jirovecii pneumonia surveillance study.
Rebecca Hilary ProudfootRobert S PhillipsPublished in: Archives of disease in childhood (2021)
PJP in children treated for malignant disease is rare. Breakthrough infection despite prophylaxis with co-trimoxazole may represent pathogen resistance or non-compliance. Further consideration of the use of PJP prophylaxis during acute myeloid leukaemia and non-Hodgkin's lymphoma treatment is warranted, alongside appraisal of the clinical implications of the possible marrow suppressive effects of co-trimoxazole and its interactions with methotrexate.
Keyphrases
- respiratory failure
- liver failure
- public health
- young adults
- emergency department
- intensive care unit
- palliative care
- bone marrow
- dendritic cells
- acute myeloid leukemia
- cross sectional
- hodgkin lymphoma
- candida albicans
- low dose
- extracorporeal membrane oxygenation
- aortic dissection
- mechanical ventilation
- replacement therapy